Publications by authors named "Sevgi B Rodan"

Claim this Profile
T
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
Elise Isabel, Kevin P Bateman, Nathalie Chauret, Wanda Cromlish, Sylvie Desmarais, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Jacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish, Sylvie Desmarais, Le T Duong, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of alpha(v)beta3 integrins in osteoclast function.
Ichiro Nakamura, Le T Duong, Sevgi B Rodan, Gideon A Rodan

J Bone Miner Metab· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a potent and selective non-basic cathepsin K inhibitor.
Chun Sing Li, Denis Deschenes, Sylvie Desmarais, Jean-Pierre Falgueyret, Jacques Yves Gauthier, Sevgi B Rodan

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
James T Palmer, Clifford Bryant, Dan-Xiong Wang, Dana E Davis, Eduardo L Setti, Sevgi B Rodan, Gideon Rodan

J Med Chem· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.
Amy E Zartman, Le T Duong, Carmen Fernandez-Metzler, George D Hartman, Chih-Tai Leu, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.
David B Whitman, Ben C Askew, Le T Duong, Carmen Fernandez-Metzler, Wasyl Halczenko, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative.
Michael J Breslin, Mark E Duggan, Wasyl Halczenko, George D Hartman, Le T Duong, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.
Paul J Coleman, Karen M Brashear, Ben C Askew, John H Hutchinson, Carol A McVean, Gideon A Rodan, Sevgi B Rodan

J Med Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.
Joël Robichaud, Christopher Bayly, Renata Oballa, Peppi Prasit, Christophe Mellon, Sevgi B Rodan

Bioorg Med Chem Lett· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.
Jiabing Wang, Michael J Breslin, Paul J Coleman, Mark E Duggan, Cecilia A Hunt, Sevgi B Rodan, Gideon A Rodan

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.
James J Perkins, L T Duong, Carmen Fernandez-Metzler, George D Hartman, Donald B Kimmel, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.
John H Hutchinson, Wasyl Halczenko, Karen M Brashear, Michael J Breslin, Paul J Coleman, Gideon A Rodan, Sevgi B Rodan

J Med Chem· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
Joël Robichaud, Renata Oballa, Peppi Prasit, Jean-Pierre Falgueyret, M David Percival, Sevgi B Rodan

J Med Chem· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.
Michael J Breslin, Mark E Duggan, Wasyl Halczenko, Carmen Fernandez-Metzler, Cecilia A Hunt, Sevgi B Rodan

Bioorg Med Chem Lett· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.
Karen M Brashear, Cecilia A Hunt, Brian T Kucer, Mark E Duggan, George D Hartman, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.
Bradley P Feuston, J Chris Culberson, Mark E Duggan, George D Hartman, Chih-Tai Leu, Sevgi B Rodan

J Med Chem· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors.
Robert M Rydzewski, Clifford Bryant, Renata Oballa, Gregg Wesolowski, Sevgi B Rodan

Bioorg Med Chem· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.
Paul J Coleman, Ben C Askew, John H Hutchinson, David B Whitman, James J Perkins, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
Robert S Meissner, James J Perkins, Le T Duong, George D Hartman, William F Hoffman, Gideon A Rodan, Sevgi B Rodan

Bioorg Med Chem Lett· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
Paul J Coleman, Karen M Brashear, Cecilia A Hunt, William F Hoffman, John H Hutchinson, Sevgi B Rodan, Gideon A Rodan

Bioorg Med Chem Lett· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis